The thalidomide tragedy is now, and always will be, part of Grünenthal's company history. Grünenthal and its family shareholders greatly regret the consequences of the thalidomide tragedy. It is a matter of moral importance to Grünenthal to be actively involved in charitable efforts to improve the situation of thalidomide-affected people on a sustainable basis. We seek to work together with those affected by thalidomide to devise projects for the provision of specific needs-based support.
Fifty years ago, on May 27, 1968, the so-called "Contergan trial" began before the Grand Criminal Court of the Regional Court of Aachen.
Thalidomide tragedy is surrounded by questions. Misinterpretations follow details about the development of the drug.
On 28 February 2017, the Fourth Amendment of the Contergan Foundation Act was published in the German Federal Law Gazette. It has now entered into force retroactively with effect from 1 January 2017. The document as PDF including all changes can be found under this link:More information
Our position is clear: There is an established financial support system for people affected by Thalidomide throughout Europe. The Contergan foundation*, in which Grünenthal has paid more than 100 million Euros, supports affected individuals in 38 countries with monthly individual payments between 675 € and 7.622 € including those affected in Spain, provided that their mothers took a Thalidomide containing product from Grünenthal.